|
Fig. 1. Expression pattern of EDEN-BP during Xenopus early development. Embryos were collected at different stages: neurula, stage 18 (A); tailbud, stage 25 (B,C,G) and stage 27 (D,F); tadpole, stage 31 (E). (A) Dorsal view, (B-G) lateral views; anterior left. Embryos were processed for whole-mount in situ hybridization using an EDEN-BP antisense (A,B,D,E), or sense (C) probe, or for whole-mount immunohistochemistry using an anti-EDEN-BP antiserum (F), or the corresponding pre-immune serum (G). The asterisks in B, D, E and F highlight the higher amount of EDEN-BP mRNA or protein in the presomitic mesoderm.
|
|
Fig. 2. EDEN-BP morpholinos affect somite segmentation in Xenopus embryos. (A) Xenopus embryos were left uninjected (lane 1), or were injected at the two-cell stage into both blastomeres with a mixture of 25 ng of each EDEN-BP morpholino, in the absence (lane 2) or presence of (2 fmol, lane 3; 0.5 fmol, lane 4) EDEN-BP mRNA. Total protein extracts from embryos collected at stage 25 (tailbud) were analyzed by western blotting using an anti-EDEN-BP antiserum (upper panel) and an anti-cdc2 A17 monoclonal antibody (lower panel). (B-Gâ²) Embryos were injected into one blastomere at the two-cells stage with 50 ng of control morpholinos (C-Mo), 25 ng of each EDEN-BP-Mo (E-Mo), or 25 ng of each EDEN-BP-Mo and 2 fmol of EDEN-BP mRNA (E-Mo+R). They were allowed to develop until stage 26 and were then processed for immunohistochemistry with the myotome-specific 12/101 monoclonal antibody (B-Dâ²), or for in situ hybridization with a MHC4 probe (E-Gâ²). Only photographs of the injected sides are shown. Bâ²-Gâ² are higher magnifications of B-G, respectively. Asterisks highlight successive somites for embryos showing segmentation.
|
|
Fig. 4. EDEN-BP morpholinos alter presegmentation in the PSM. Embryos were injected in one blastomere at the two-cell stage with 25 ng of each EDEN-BP morpholino. (A-D) Lateral views of stage 25/26 embryos stained for ESR5 (A,B) or X-Delta2 (C,D). (A,C) Non-injected sides, and (B,D) injected sides of the same embryos. TBD, tailbud domain. S1 to S4, Somitomeres 1 to 4. (E-G) Posterior views of stage 20 embryos stained for ESR9, representative of phase I (E), II (F) and III (G) of the dynamic mode of expression of ESR9. (Eâ²-Gâ²) Schematic drawings of E-G.
|
|
Fig. 6. Evidence for other targets of EDEN-BP than XSu(H) in the segmentation process. (A-F) Embryos were injected in one blastomere at the two-cell stage with 2 fmol of XSu(H)1 mRNA. They were allowed to develop to stage 28 (A,B) or stage 26 (C-F), and then stained with the 12/101 monoclonal antibody (A,B), or stained with the ESR5 (C,D) or X-Delta2 (E,F) probes. (A,C,E) Injected sides, and (B,D,F) non-injected sides of the same embryos. Asterisks highlight successive somites in B. TBD, tailbud domain; S1 to S4, somitomeres 1 to 4. (G) Embryos were injected with 25ng of each E-Mo, and 0, 1, 2.5 or 5 ng of each X-Mo as indicated. The graph represents the percentage of abnormally segmented embryos, normalized to 100% for the embryos injected with E-Mo only. The total number of embryos examined for each of these conditions is indicated above each bar.
|
|
celf1 (CUGBP Elav-like family member 1) gene expression in Xenopus laevis embryos, NF stage 18, assayed by in situ hybridization, lateral view, anterior left, dorsal up.
|
|
celf1 (CUGBP Elav-like family member 1) gene expression in Xenopus laevis embryos, NF stage 25, as assayed by in situ hybridization, lateral view, dorsal up, anterior left.
|
|
celf1 ( CUGBP Elav-like family member 1) gene expression in Xenopus laevis embryos, NF stage 27, as assayed by in situ hybridization, lateral view, anterior left, dorsal up
|
|
celf1 (CUGBP Elav-like family member 1) gene expression in Xenopus laevis embryos, NF stage 31, as assayed by in situ hybridization, lateral view, anterior left, dorsal up.
|
|
Fig. 3.
Analysis of embryos injected with anti-EDEN-BP antibodies. (A-D) Embryos were injected into one blastomere at the two-cell stage with control (non-immune, C-Ab) or anti-EDEN-BP (E-Ab) antibodies. They were allowed to develop until stage 39 and then were stained with the myotome-specific 12/101 monoclonal antibody. C and D are higher magnifications of the lower embryos in A and B, respectively. (A,C) Injected sides and (B,D) non-injected sides of the same embryos. (E-G) Hematoxylin and Eosin-stained horizontal sections of stage 39 embryos injected at the two-cell stage with 200 ng of anti-EDEN-BP antibodies. (F,G) Higher magnifications of the somites of the non-injected (F) and injected (G) sides. n, notochord; s, somite. Arrow indicates the injected side. Asterisks highlight successive somites for embryos showing segmentation. Scale bars: 50 μm.
|